Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shahnaz Shahinfar

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
American Journal of Hypertension|October 14, 2003
A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertensionBeth Soffer, Zhongxin Zhang, Kenneth Miller, et al.
Kidney International|March 13, 2003
Dialysis delayed is death prevented: a clinical perspective on the RENAAL studyMerlin C Thomas, Mark E Cooper, Shahnaz Shahinfar, et al.
Kidney International. Supplement|January 25, 2005
Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL StudyShahnaz Shahinfar, Tanya Dickson, Zhongxin Zhang, et al.
Clinical Cardiology|April 9, 2005
Losartan and end-organ protection--lessons from the RENAAL studyPeter R Kowey, Tania Z Dickson, Zhongxin Zhang, et al.
Expert Opinion on Pharmacotherapy|March 24, 2006
Losartan: lessons learned from the RENAAL studyShahnaz Shahinfar, Paulette A Lyle, Zhongxin Zhang, et al.
Kidney International. Supplement|October 16, 2004
Detecting and managing patients with type 2 diabetic kidney disease: proteinuria and cardiovascular diseaseWilliam E Mitch, Shahnaz Shahinfar, Tania Z Dickson, et al.
Journal of Clinical Pharmacology|August 7, 2002
A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertensionThomas Wells, Virginia Frame, Beth Soffer, et al.
Kidney International|August 26, 2004
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathyAnupama Mohanram, Zhongxin Zhang, Shahnaz Shahinfar, et al.
Diabetes Care|September 28, 2006
Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetesWolfgang C Winkelmayer, Zhongxin Zhang, Shahnaz Shahinfar, et al.
Kidney International. Supplement|October 16, 2004
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathyCharles M Alexander, Paulette A Lyle, William F Keane, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
American Journal of Hypertension|October 14, 2003
A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertensionBeth Soffer, Zhongxin Zhang, Kenneth Miller, et al.
Kidney International|March 13, 2003
Dialysis delayed is death prevented: a clinical perspective on the RENAAL studyMerlin C Thomas, Mark E Cooper, Shahnaz Shahinfar, et al.
Kidney International. Supplement|January 25, 2005
Baseline predictors of end-stage renal disease risk in patients with type 2 diabetes and nephropathy: new lessons from the RENAAL StudyShahnaz Shahinfar, Tanya Dickson, Zhongxin Zhang, et al.
Clinical Cardiology|April 9, 2005
Losartan and end-organ protection--lessons from the RENAAL studyPeter R Kowey, Tania Z Dickson, Zhongxin Zhang, et al.
Expert Opinion on Pharmacotherapy|March 24, 2006
Losartan: lessons learned from the RENAAL studyShahnaz Shahinfar, Paulette A Lyle, Zhongxin Zhang, et al.
Kidney International. Supplement|October 16, 2004
Detecting and managing patients with type 2 diabetic kidney disease: proteinuria and cardiovascular diseaseWilliam E Mitch, Shahnaz Shahinfar, Tania Z Dickson, et al.
Journal of Clinical Pharmacology|August 7, 2002
A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertensionThomas Wells, Virginia Frame, Beth Soffer, et al.
Kidney International|August 26, 2004
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathyAnupama Mohanram, Zhongxin Zhang, Shahnaz Shahinfar, et al.
Diabetes Care|September 28, 2006
Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetesWolfgang C Winkelmayer, Zhongxin Zhang, Shahnaz Shahinfar, et al.
Kidney International. Supplement|October 16, 2004
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathyCharles M Alexander, Paulette A Lyle, William F Keane, et al.
Pageof 5